Up-front Hepatic Resection for Metastatic Colorectal Cancer Results in Favorable Long-term Survival
- 5 October 2012
- journal article
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 20 (1) , 295-304
Abstract
Hepatic metastasis from colorectal cancer (CRC) is best managed with a multimodal approach; however, the optimal timing of liver resection in relation to administration of perioperative chemotherapy remains unclear. Our strategy has been to offer up-front liver resection for patients with resectable hepatic metastases, followed by post–liver resection chemotherapy. We report the outcomes of patients based on this surgical approach. A retrospective review of all patients undergoing liver resection for CRC metastases over a 5-year period (2002–2007) was performed. Associations between clinicopathologic factors and survival were evaluated by the Cox proportional hazard method. A total of 320 patients underwent 336 liver resections. Median follow-up was 40 (range 8–80) months. The majority (n = 195, 60.9 %) had metachronous disease, and most patients (n = 286, 85 %) had a major hepatectomy (>3 segments). Thirty-six patients (11 %) received preoperative chemotherapy, predominantly for downstaging unresectable disease. Ninety-day mortality was 2.1 %, and perioperative morbidity occurred in 68 patients (20.2 %). Actual disease-free survival at 3 and 5 years was 46.2 % and 42 %, respectively. Actual overall survival (OS) at 3 and 5 years was 63.7 % and 55 %, respectively. Multivariate analysis identified four factors that were independently associated with differences in OS (hazard ratio; 95 % confidence interval): size of metastasis >6 cm (2.2; 1.3–3.5), positive lymph node status of the primary CRC (N1 (2.0; 1.0–3.8), N2 (2.4; 1.2–4.9)), synchronous disease (2.1; 1.3–3.5), and treatment with chemotherapy after liver resection (0.42; 0.23–0.75). Up-front surgery for patients with resectable CRC liver metastases, followed by chemotherapy, can lead to favorable OS.Keywords
This publication has 32 references indexed in Scilit:
- Improved Survival in Metastatic Colorectal Cancer Is Associated With Adoption of Hepatic Resection and Improved ChemotherapyJournal of Clinical Oncology, 2009
- Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trialThe Lancet, 2008
- Complete Response of Colorectal Liver Metastases After Chemotherapy: Does It Mean Cure?Journal of Clinical Oncology, 2006
- Influence of Preoperative Chemotherapy on the Risk of Major Hepatectomy for Colorectal Liver MetastasesAnnals of Surgery, 2006
- Neoadjuvant Chemotherapy Before Liver Resection for Patients With Unresectable Liver Metastases From Colorectal CarcinomaJournal of Clinical Oncology, 2005
- Perioperative complications in patients undergoing major liver resection with or without neoadjuvant chemotherapyJournal of Gastrointestinal Surgery, 2003
- Resection rate and effect of postoperative chemotherapy on survival after surgery for colorectal liver metastasesBritish Journal of Surgery, 2001
- Resection of colorectal liver metastasesWorld Journal of Surgery, 1995
- Resection of Hepatic Metastases from Colorectal Cancer Biologic PerspectivesAnnals of Surgery, 1989
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958